Asthma – Landscape & Forecast – Disease Landscape & Forecast
The asthma therapy market consists of many well-established treatments, including inhaled agents (e.g., GlaxoSmithKline’s Advair / Seretide, AstraZeneca’s Symbicort, Boehringer Ingelheim’s Spiriva), oral drugs (e.g., montelukast), and biologics (e.g., Roche / Novartis’s Xolair, GlaxoSmithKline’s Nucala). However, market dynamics are evolving as branded generic and generic alternatives to inhaled blockbuster agents continue to launch and new biologics targeting niche populations within the severe asthma segment are approved. These events have increased—and will continue to increase—competition in this lucrative market. With the impending entry of an additional biological therapy, an oral agent targeting severe asthma, and a SABA/ICS combination agent; the launch of branded generic and generic inhaled drugs in new markets; and the launch of LABA/LAMA/ICS combination agents, the asthma market is poised to experience substantial change over the next decade.
Questions answered:
- What are KOLs’ insights on current inhaled branded, branded generic, and generic treatments? What is / will be the market impact of branded generic and generic inhaled therapies?
- What are KOLs’ perceptions of currently marketed asthma biologics (Xolair, Nucala, Teva’s Cinqair / Cinqaero, AstraZeneca’s Fasenra, Sanofi / Regeneron’s Dupixent)? According to physicians, where do these drugs fit in the treatment algorithm? What drives physicians’ choice of a biologic for severe, refractory asthma?
- How will the market evolve over the next 10 years given the launch of additional inhaled, oral, and biological products? Will the entry of triple LABA/LAMA/ICS combination agents and SABA/ICS combination agents have a substantial effect on the sales and patient share of currently marketed asthma therapies? Where do physicians see these combination therapies fitting in the treatment algorithm?
Scope:
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 24 country-specific interviews with thought leaders.
Epidemiology: Number of diagnosed and drug-treated prevalent cases of asthma; number of diagnosed and drug-treated prevalent cases of intermittent / mild persistent and moderate / severe persistent asthma.
Emerging therapies: Preregistered: 1 drugs; Phase III: 3 drugs; Phase II: 9 drugs; coverage of one select Phase I product.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Asthma - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- June 2023
- March 2023
- Q4 2022
- December 2022
- October 2022
- Market outlook
- Key findings
- Market share of drug classes for asthma: 2021
- Market share of drug classes for asthma: 2031
- Asthma SWOT analysis
- Market drivers and constraints
- What factors are driving the market for asthma?
- What factors are constraining the market for asthma?
- Market share of drug classes in the moderate / severe asthma population: 2021
- Market share of drug classes in the moderate / severe asthma population: 2031
- Market share of asthma therapies by region: 2021, 2026, 2031
- Major-market sales in intermittent / mild and moderate / severe asthma populations: 2021-2031
- Major-market patient share of biologics in the moderate / severe asthma population: 2021-2031
- Drug-class-specific trends
- Major-market sales of inhaled corticosteroids in asthma: 2021-2031
- Market share of inhaled corticosteroids within the ICS drug class: 2021
- Market share of inhaled corticosteroids within the ICS drug class: 2031
- Major-market sales of inhaled corticosteroids for intermittent / mild and moderate / severe asthma: 2021-2031
- Major-market sales of LABA/ICS FDCs in asthma: 2021-2031
- Major-market sales of salmeterol / fluticasone propionate for asthma by brand and generic formulations: 2021-2031
- Major-market sales of formoterol / budesonide for asthma by brand and generic formulations: 2021-2031
- Major-market sales of LABA/ICS FDCs in the intermittent / mild and moderate / severe asthma populations: 2021-2031
- Major-market sales of LAMAs in asthma: 2021-2031
- Major-market sales of LABA/LAMA/ICS FDCs in asthma: 2021-2031
- Major-market sales of omalizumab by region: 2021-2031
- Major-market sales of anticytokines in asthma: 2021-2031
- Major-market sales of anticytokines in asthma by MOA: 2021-2031
- Major-market sales of albuterol in asthma by brand and generic formulations: 2021-2031
- Major-market patient shares of albuterol in asthma by brand and generic formulations: 2021-2031
- Key findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Atopic vs. nonatopic asthma
- Environmental vs. genetic risk factors
- Models for asthma caused by environmental risk factors
- Effect of the allergic cascade in asthma
- Disease pathophysiology
- Pathophysiology and phenotypes
- Allergen-induced inflammation process
- Key pathways and drug targets
- Mechanism of action of biological therapies in asthma
- Disease overview
- Epidemiology
- Key findings
- Note about our epidemiology estimates
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed symptomatic or medically controlled 12-month prevalent cases of asthma
- Diagnosed symptomatic or medically controlled 12-month prevalent cases of asthma: 2021-2031
- Disease definition
- Methods
- Severity populations used in the market forecast
- Sources used for diagnosed symptomatic or medically controlled 12-month prevalent cases of asthma by severity
- Diagnosed symptomatic or medically controlled 12-month prevalent cases of asthma by severity: 2021-2031
- Diagnosed symptomatic or medically controlled drug-treated 12-month prevalent cases of intermittent / mild asthma: 2021-2031
- Diagnosed symptomatic or medically controlled drug-treated 12-month prevalent cases of moderate / severe asthma: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for asthma
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for asthma
- Key current treatments used for asthma
- Market events impacting the use of key current therapies in asthma
- Advantages and disadvantages of ICSs
- Expert insight: ICSs
- Advantages and disadvantages of LABAs
- LABA/ICS fixed-dose combinations
- Advantages and disadvantages of LABA/ICS fixed-dose combinations
- Expert insight: LABA/ICS fixed-dose combinations
- Advantages and disadvantages of salmeterol / fluticasone propionate
- Advantages and disadvantages of formoterol / budesonide
- Advantages and disadvantages of Foster / Fostair (formoterol / beclomethasone)
- Advantages and disadvantages of Dulera (formoterol / mometasone)
- Advantages and disadvantages of Flutiform / Abriff (formoterol / fluticasone propionate)
- Advantages and disadvantages of Breo / Relvar (vilanterol / fluticasone furoate)
- Atectura Breezhaler / Bemrist Breezhaler (indacaterol / mometasone)
- Advantages and disadvantages of Atectura Breezhaler / Bemrist Breezhaler (indacaterol / mometasone)
- Advantages and disadvantages of montelukast
- Tiotropium
- Advantages and disadvantages of tiotropium
- Expert insight: LAMAs
- Expert insight: LABA/LAMA/ICS fixed-dose combinations
- Advantages and disadvantages of Trelegy
- Advantages and disadvantages of Enerzair Breezhaler
- Advantages and disadvantages of Trimbow
- Xolair (omalizumab)
- Advantages and disadvantages of Xolair
- Expert insight: Xolair
- Advantages and disadvantages of IL-5 antagonists
- Expert insight: IL-5 antagonists
- Nucala (mepolizumab)
- Advantages and disadvantages of Nucala
- Cinqair / Cinqaero (reslizumab)
- Advantages and disadvantages of Cinqair / Cinqaero
- Ongoing clinical development of Cinqair / Cinqaero
- Fasenra (benralizumab)
- Advantages and disadvantages of Fasenra
- Ongoing clinical development of Fasenra
- Dupixent (dupilumab)
- Advantages and disadvantages of Dupixent (dupilumab)
- Ongoing clinical development of Dupixent
- Expert insight: Dupixent
- Tezspire (tezepelumab)
- Advantages and disadvantages of Tezspire (tezepelumab)
- Expert insight: Tezspire
- Advantages and disadvantages of short-acting beta2 agonists
- Medical practice
- Overview
- Factors influencing drug selection in asthma
- Inhaler devices for asthma
- Expert insight: inhaler devices
- Region-specific treatment practices
- Treatment decision tree for asthma: United States
- Treatment decision tree for asthma: Europe
- Treatment decision tree for asthma: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in asthma
- Top unmet needs in asthma: current and future attainment
- Expert insight: unmet need in asthma
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for asthma
- Estimated launch dates of key emerging therapies for the treatment of asthma
- Tezepelumab
- Tezepelumab profile
- Analysis of the clinical development program for tezepelumab
- Expert insight: tezepelumab
- Expectations for launch and sales opportunity for tezepelumab in asthma
- Key ongoing clinical trials of depemokimab in the treatment of asthma
- Expert insight: depemokimab
- Breztri Aerosphere / Trixeo Aerosphere (formoterol / glycopyrronium / budesonide)
- Profile of Breztri Aerosphere / Trixeo Aerosphere
- Analysis of the clinical development program for Breztri Aerosphere / Trixeo Aerosphere
- Expert insight: Breztri Aerosphere / Trixeo Aerosphere
- Expectations for launch and sales opportunity of Breztri Aerosphere / Trixeo Aerosphere in asthma
- PT-027 (albuterol / budesonide)
- Profile of PT-027
- Analysis of the clinical development program for PT-027
- Expert insight: PT-027
- Expectations for launch and sales opportunity of PT-027 in asthma
- Masitinib
- Masitinib profile
- Analysis of the clinical development program for masitinib
- Expert insight: masitinib
- Expectations for launch and sales opportunity of masitinib in asthma
- Early-phase pipeline analysis
- Select compounds in early-phase development for asthma
- Key discontinuations and failures in asthma
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in asthma: United States
- General reimbursement environment: United States
- Key market access considerations in asthma: EU5
- General reimbursement environment: EU5
- Key market access considerations in asthma: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Asthma bibliography
- Key findings
Shubhendu Ghosh, Ph.D., Senior Healthcare Research & Data Analyst, Immune and Inflammation. Dr. Ghosh’s focus is the asthma and urticaria therapy markets. Previously, he was an associate editor at Nature Structural & Molecular Biology and a copy editor at Nature Medicine. He was also a scientific and developmental editor at Nature Research Editing Service. He holds a Ph.D. in biomedical sciences from the University of Massachusetts Medical School, a B.Sc. in microbiology from Delhi University, and an M.Sc. in biotechnology from Madurai Kamaraj University.
Dr. Harpreet Kaur, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she was awarded a National Clinical Research Fellowship by the Indian Council of Medical Research (ICMR) and worked as a clinical scientist in the broader area of adolescent reproductive health. She obtained her master’s degree in social epidemiology from the Tata Institute of Social Sciences in Mumbai and graduated with a degree in dentistry from Punjab University in Chandigarh.